Page 913 890 National Heart, Lung, and Blood Institute-Continued Hemoglobin Disorders. Minorities and Heart Disease Minority Outreach.. Smoking and Body Weight Smoking during Pregnancy Women and Aspirin 822 819 824 901 821 895 784 896 827 923 923 982 National Institute of Allergy and Infectious Diseases. Introduction of Witnesses AIDS. 955 Page 984 955 948 National Institute of Allergy and Infectious Diseases-Continued Pediatric. Women and Children Asthma and Allergic Diseases.. Urban Asthma Study. Average Cost Increase Project Grants Cost Savings from Development. 987 989 957 977 978 968 958 1045 National Eye Institute ..... Age Related Macular Degeneration AIDS.... 1046 1072 1064 1061 1080 1052 1081 1057 National Eye Institute-Continued Ready to be Implemented Results .. Vision Improvement Opportunities Vision Research, Average Cost........ Length of Awards ........ Price Index .......... Diabetes .. Vision Disorders.. Cost Containment, Impact on Clinical Trials Lost ....... Ready to Exploited Core Center Grants Funding Adjustments Average Cost Increase Supported ....... 1052 1079 1082 1083 1057 1078 1068 1070 1052 Page National Eye Institute-Continued Improvements Opportunities in Decade of The Brain 1064 National Institute of Child Health and Human Development 1135 1167 1175 1136, 1157, 1179 1176 1189 1174 1195 1187 1166 1153, 1157, 1191 1182 1137, 1144 1153 1167 1165 1185 1136, 1144, 1147, 1159 1148 1145 1146 1157 1173 1161, 1173 1150, 1155 1167, 1170 1150 1151. 1152 1151 1179 1176 1145 1157 1136 1184 1154 1180 1191 1154 1181 1163 1136, 1146 1156 1138 1164 National Institute of Child Health and Human Development-Continued Statement of the Director ........ Development 1136 1176 1287 1249 National Institute of Environmental Health Sciences. 1247 Accomplishments, summary of recent 1318 Agricultural chemicals......... 1339 Farm chemicals and health. 1326 AIDS: Drug safety. 1328, 1329 HIV...... 1336 Air pollution and health 1325 Pollution research 1259 Quality 1253 Asbestos ...... 1249, 1250 Biomarkers... 1249, 1335 Dose-response of. 1337 Risk 1331 Biomedical Research and Development Price Index. 1290 Centers ..... 1292 Established. 1333 New 1333 Characterization of budget Clean Air Act .... 1255, 1256, 1261, 1266, 1269, 1277, 1287, 1339 Comparative mechanisms 1335 Conclusion......... Contracts... 1266 Coordination 1256 Dioxin exposure and effects 1331 Direction of current research... 1319 Dissemination of information 1277 Early fetal development........... 1324 Eastern Europe and environmental health. 1339 Electromagnetic fields ...... 1255, 1329 Emerging opportunities and future plans EPA funds ........ 1259 Fibers ....... 1325 Funding levels... 1271 Gene therapy safety. 1329 Genes, the environment, cancer and aging. 1334 Genetics .......... 1251, 1252 Grain dust and lung disease.. 1330 Hormones and health 1335 Indoor air and asthma.. 1285 Infant mortality .... 1273, 1284 Intramural research 1267 Introduction ....... 1247 Justification of the budget estimates.. 1297 Lead .......... 1248, 1273, 1281, 1326 Long-term Plan, cost of . 1279 Planning 1338 1320 |